Recent developments in the understanding of bradykinin receptors. |
| |
Authors: | R M Burch D J Kyle |
| |
Affiliation: | Nova Pharmaceutical Corporation, Baltimore, MD 21224. |
| |
Abstract: | The dramatic activities of bradykinin and related peptides as mediators of pain, inflammation and hypotension have been intensely studied for several decades. More recently, the involvement of bradykinin in regulation of ion transport by epithelia, hormone release from endocrine organs, energy metabolism, tissue growth, and leukocyte activation have become topics of study. Kininogen precursors, synthetic kallikreins, and degradative kininases have been characterized in detail with regard to catalytic mechanisms, physical structure and gene regulation; however, the actual receptors for bradykinin are still only poorly understood. This situation is caused by the lack of availability of potent, specific receptor antagonists. However, specific bradykinin receptor antagonists became available in 1985, and several very potent classes of agents are now available; also, the first bradykinin receptor has been cloned. |
| |
Keywords: | |
|
|